Clinical Trial Update: A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer [Phase 2]

View source ↗

Summary

An update on a Phase 2 study evaluating a pan-immunotherapy in patients with relapsed/refractory ovarian cancer; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Pan-immunotherapy

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED